Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV. Data ...
On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for ...
Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension, or PAH, has met its primary endpoint. Topline results from the study, called ...
Keytruda demonstrated statistically significant and clinically meaningful improvement in OS compared to pre-operative chemotherapy. KEYNOTE 522 is the fourth study of a Keytruda-based regimen in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results